Jubilant Pharmova Q2 Profit Falls 74% Despite Revenue Growth in Generics
Jubilant Pharmova reported a 74% year-on-year decline in net profit to Rs 31 crore for Q2 FY27, despite a 20% rise in total revenue to around Rs 2,360 crore. The company's EBITDA fell 27%, with margins pressured by higher operating expenses and lower availability of high-margin radiopharmaceutical products. Generics and CDMO Sterile Injectables segments showed strong revenue growth of 64% and 33%, respectively. The company also raised Rs 800 crore through non-convertible debentures for debt refinancing and capital expenditure.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (40/100). Lens Score 36/100.
Outlets measured: freepressjournal, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (38–42/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 13 Nov, 04:03 pm. Other outlets followed.
- 1